Horizon Pharma, which is planning the commercial launches of its two lead products, which treat ulcers and rheumatoid arthritis pain, respectively, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Northbrook, IL-based company, which was founded in 2004 and booked $3 million in pro forma sales last year, plans to list on the NASDAQ under the symbol HZPN. Jefferies & Co. and Piper Jaffray are the lead underwriters on the deal. No pricing terms were disclosed.
